Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute intravenous epoetin alpha effects on cardiac function in heart failure
ACTRN12607000042448Phase 2Recruiting
- Sponsor
- John Hunter Hospital
- Start
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of epoetin alfa in heart failure (HF), sponsored by John Hunter Hospital. Primary endpoint: Improved cardiac function including increased ejection fraction. Started Aug 2006; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ACTRN12607000042448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000042448.